Repurposing HAMI3379 to Block GPR17 and Promote Rodent and Human Oligodendrocyte Differentiation

Area of Science:

• Neuroscience
• Pharmacology
• Drug Discovery

Background:

• Drug repurposing is a key strategy in modern drug discovery.
• HAMI3379 was initially developed as a CysLT2 receptor antagonist for cardiovascular and inflammatory conditions.
• The G protein-coupled receptor 17 (GPR17) is an orphan receptor implicated in oligodendrocyte function.

Purpose of the Study:

• To investigate HAMI3379 as a potential antagonist of the orphan GPR17 receptor.
• To evaluate the effect of GPR17 blockade on oligodendrocyte maturation and differentiation.
• To explore the therapeutic potential of targeting GPR17 for remyelination.

Main Methods:

• In vitro assays using recombinant and endogenous GPR17 in various cell types.
• Assessment of oligodendrocyte maturation and differentiation in primary rodent and human cells.
• Utilizing GPR17 knockout mice models to confirm target specificity.

Main Results:

• HAMI3379 was identified as a potent antagonist of human, rat, and mouse GPR17.
• GPR17 blockade by HAMI3379 enhanced oligodendrocyte maturation in rodents.
• HAMI3379 promoted human oligodendrocyte differentiation, counteracting GPR17 activation-induced impairment.

Conclusions:

• HAMI3379 is a novel GPR17 antagonist with significant implications for neuroregeneration.
• Targeting GPR17 with HAMI3379 shows promise for enhancing remyelination strategies.
• This study highlights the potential of HAMI3379 for treating demyelinating diseases.